THE CONTRIBUTION OF FLOW CYTOMETRY TO THE IDENTIFICATION OF CD5+ DIFFUSE LARGE B CELL LYMPHOMA (CD5+ DLBCL) (SIE 2026) - Oct 6, 2026 - Abstract #SP066; "Median event-free survival was 20 months (range 9-72) in pts treated with curative intent (mainly R-CHOP) and 6 months (range 1-9) in those treated with R-miniCOMP. Our findings highlight the value of FC as a complementary tool for identifying CD5+ DLBCL at higher risk of progression. Furthermore, FC may improve diagnos- tic sensitivity particularly in the detection of rare events such as occult CNS involvement."
B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Indolent Lymphoma • Large B Cell Lymphoma • Lymphoma • Non-Hodgkin's Lymphoma • Respiratory Diseases • CD5
|
|
E. Maiolo1; S. Bellesi1; C. Iacovelli1; E. Alma2; F. Bellisario2; M. Viscovo2,3; G. Schiaffini2,3; A. Bakacs4; D'Alò F2,3; S. Hohaus2,3
|